Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses the results of the Phase I/II study (NCT02227199) aiming to improve post-autologous stem cell transplant (ASCT) results with brentuximab vedotin (BV) and ICE (ifosfamide, carboplatin and etoposide) therapy in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) patients. While many patients experienced mild adverse events, the overall safety profile was deemed acceptable. Findings suggest that BV-ICE has potential as a salvage regimen for R/R cHL patients, especially when administered prior to ASCT. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.